Enhanced mitochondrial biogenesis in CD8+ CAR T cells, demonstrated by increased mitochondrial mass, correlates positively with the efficacy of CAR T‐cell therapy, suggesting that enhancing mitochondrial biogenesis could potentiate cellular immunotherapies in CLL.[35] Crucially, CD8+ T cells in juvenile SLE exhibit reduced cytotoxicity, linked to heightened type I interferon signaling, mitochondrial dysfunction, and metabolic imbalance. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.